Zevra has sold its US Food and Drug Administration (FDA) priority review voucher (PRV) for $150m to an undisclosed party.
A Johnson & Johnson unit working to resolve massive cancer litigation in bankruptcy court was accused by a former head of the ...
Stifel has initiated Compass Pathways (NASDAQ:CMPS) with a buy rating saying that stakeholders are starting to agree there is ...
Novartis' dividend yield currently stands at 3.58%, which is significantly higher than that of the healthcare sector. Read ...
We recently published a list of the 10 Best Vaccine Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against the other ...
For Zevra Therapeutics, last year’s approval of the rare lysosomal storage disorder drug Miplyffa appears to be the gift that ...
Mr Johnson is an American entrepreneur and venture capitalist, best known for his anti-aging attempt that he refers to as ...
A year after the FDA rejected its marketing application for CD20xCD3 bispecific antibody odronextamab to treat two common ...
Bryan Supran, non-executive director and representative of Pfizer, stepped down from the Haleon board of directors. Elizabeth Holmes, the disgraced founder of Theranos, will remain in prison after ...
Eli Lilly announced plans for four new pharmaceutical manufacturing sites to produce domestic medicine production in the ...
Reckitt's growth strategy drives momentum despite litigation risks. High-margin brands & dividends shine, but baby food ...
A big change may be coming to vape shops in Tennessee. A proposed bill in the state House of Representatives and Senate would ban all non-Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results